The past decade has seen major advances in therapies for type 2 diabetes, leading to a wide array of treatment options. Management should involve a patient-centred approach with individualised glycaemic targets and selection of medications based on comorbidities, cost and patient preference.
- Early and optimal glycaemic control in patients with type 2 diabetes is imperative for reducing microvascular and potentially macrovascular complications.
- Glycated haemoglobin (HbA1c) remains the key focus of glycaemic management although targets should be individualised based on age, comorbidities and life expectancy.
- There is a vast array of therapies available and treatment algorithms provided by the Australian Diabetes Society offer guidance on treatment selection.
- Treatment choice should be guided by patient comorbidities, adverse effect profile, acceptability of the method of administration and cost (PBS subsidy).
- Metformin remains first-line treatment unless contraindicated. Insulin may be considered at any stage, particularly where control is poor (HbA1c above 75 mmol/mol [9%]).
- Patients with pre-existing cardiovascular disease can be safely managed with new agents, including some DPP4-inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors, and some therapies may offer cardiovascular mortality benefit.
Picture credit: FERTNIG/ISTOCKPHOTO.COM Model used for illustrative purposes only